A β-Cyclodextrin-Albumin Conjugate for Enhancing Therapeutic Efficacy of Cytotoxic Drugs

Abstract

Enhancing the selectivity of anticancer drugs currently used in the clinic is of great interest in order to propose patients more efficient chemotherapies with less side effects. In this context, we developed a -cyclodextrin trimer that binds to circulating albumin to form the corresponding bioconjugate in the bloodstream. This later can then entrap doxorubicin following its i.v. administration via the formation of a host-guest inclusion complex and deliver the drug in tumors. In this study, we demonstrate that the -cyclodextrin trimer improves the therapeutic efficacy of doxorubicin for the treatment of a subcutaneous murine Lewis lung carcinoma (LLC)